List of Excipients in API emtricitabine, rilpivirine, and tenofovir alafenamide
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing emtricitabine, rilpivirine, and tenofovir alafenamide
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| A-S Medication Solutions | ODEFSEY | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 | CELLULOSE, MICROCRYSTALLINE | 2033-02-15 |
| A-S Medication Solutions | ODEFSEY | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 | CROSCARMELLOSE SODIUM | 2033-02-15 |
| A-S Medication Solutions | ODEFSEY | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 | FERROSOFERRIC OXIDE | 2033-02-15 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for emtricitabine, rilpivirine, and tenofovir alafenamide
Excipient focus: CELLULOSE, MICROCRYSTALLINE
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 20
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants containing POLYSORBATE 20
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants not containing POLYSORBATE 20
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | emtricitabine, rilpivirine, and tenofovir alafenamide | 50090-2340 |
| >Company | >Ingredient | >NDC |
emtricitabine, rilpivirine, and tenofovir alafenamide drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
